Adam Crystal's most recent trade in Tango Therapeutics Inc was a trade of 27,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 1, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Tango Therapeutics Inc | Adam Crystal | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2026 | 27,000 | 368,040 | - | - | Stock Option (Right to Buy) | |
| Tango Therapeutics Inc | Adam Crystal | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.20 per share. | 01 May 2026 | 27,000 | 142,743 | - | 5.2 | 140,400 | Common Stock |
| Tango Therapeutics Inc | Adam Crystal | President, R&D | Sale of securities on an exchange or to another person at price $ 21.19 per share. | 01 May 2026 | 25,900 | 116,843 | - | 21.2 | 548,901 | Common Stock |
| Tango Therapeutics Inc | Adam Crystal | President, R&D | Sale of securities on an exchange or to another person at price $ 22.00 per share. | 01 May 2026 | 1,100 | 115,743 | - | 22.0 | 24,196 | Common Stock |
| Tango Therapeutics Inc | Adam Crystal | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2026 | 38,460 | 395,040 | - | - | Stock Option (Right to Buy) | |
| Tango Therapeutics Inc | Adam Crystal | President, R&D | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 15 Apr 2026 | 38,460 | 112,622 | - | 25 | 961,500 | Common Stock |
| Tango Therapeutics Inc | Adam Crystal | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.20 per share. | 15 Apr 2026 | 38,460 | 151,082 | - | 5.2 | 199,992 | Common Stock |
| Tango Therapeutics Inc | Adam Crystal | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2026 | 27,000 | 433,500 | - | - | Stock Option (Right to Buy) | |
| Tango Therapeutics Inc | Adam Crystal | President, R&D | Sale of securities on an exchange or to another person at price $ 21.20 per share. | 01 Apr 2026 | 27,000 | 112,622 | - | 21.2 | 572,478 | Common Stock |
| Tango Therapeutics Inc | Adam Crystal | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.20 per share. | 01 Apr 2026 | 27,000 | 139,622 | - | 5.2 | 140,400 | Common Stock |
| Tango Therapeutics Inc | Adam Crystal | President, R&D | Sale of securities on an exchange or to another person at price $ 20.11 per share. | 25 Mar 2026 | 12,000 | 112,622 | - | 20.1 | 241,320 | Common Stock |
| Tango Therapeutics Inc | Adam Crystal | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Mar 2026 | 12,000 | 460,500 | - | - | Stock Option (Right to Buy) | |
| Tango Therapeutics Inc | Adam Crystal | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.20 per share. | 25 Mar 2026 | 12,000 | 124,622 | - | 5.2 | 62,400 | Common Stock |
| Tango Therapeutics Inc | Adam Crystal | President, R&D | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 05 Mar 2026 | 20,251 | 112,622 | - | 15 | 303,765 | Common Stock |
| Tango Therapeutics Inc | Adam Crystal | President, R&D | Sale of securities on an exchange or to another person at price $ 12.77 per share. | 25 Feb 2026 | 54,345 | 132,873 | - | 12.8 | 694,208 | Common Stock |
| Tango Therapeutics Inc | Adam Crystal | President, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 284,760 | 284,760 | - | - | Stock Option (Right to Buy) | |
| Tango Therapeutics Inc | Adam Crystal | President, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 47,460 | 205,670 | - | 0 | Common Stock | |
| Tango Therapeutics Inc | Adam Crystal | President, R&D | Sale of securities on an exchange or to another person at price $ 12.26 per share. | 02 Feb 2026 | 18,251 | 187,419 | - | 12.3 | 223,708 | Common Stock |
| Tango Therapeutics Inc | Adam Crystal | President, R&D | Sale of securities on an exchange or to another person at price $ 12.90 per share. | 02 Feb 2026 | 201 | 187,218 | - | 12.9 | 2,592 | Common Stock |
| Tango Therapeutics Inc | Adam Crystal | See Remarks | Sale of securities on an exchange or to another person at price $ 2.99 per share. | 04 Feb 2025 | 7,432 | 165,061 | - | 3.0 | 22,207 | Common Stock |
| Tango Therapeutics Inc | Adam Crystal | See Remarks | Sale of securities on an exchange or to another person at price $ 3.16 per share. | 04 Feb 2025 | 6,851 | 158,210 | - | 3.2 | 21,659 | Common Stock |
| Tango Therapeutics Inc | Adam Crystal | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 318,090 | 318,090 | - | - | Stock Option (Right to Buy) | |
| Tango Therapeutics Inc | Adam Crystal | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 53,015 | 172,493 | - | 0 | Common Stock | |
| Tango Therapeutics Inc | Crystal Adam | See Remarks | Sale of securities on an exchange or to another person at price $ 12.56 per share. | 06 Feb 2024 | 4,288 | 123,561 | - | 12.6 | 53,868 | Common Stock |
| Tango Therapeutics Inc | Crystal Adam | See Remarks | Sale of securities on an exchange or to another person at price $ 12.62 per share. | 06 Feb 2024 | 4,083 | 119,478 | - | 12.6 | 51,527 | Common Stock |
| Tango Therapeutics Inc | Adam Crystal | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 279,593 | 279,593 | - | - | Stock Option (Right to Buy) | |
| Tango Therapeutics Inc | Crystal Adam | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 46,599 | 46,599 | - | 0 | Common Stock | |
| Tango Therapeutics Inc | Adam Crystal | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 487,500 | 487,500 | - | - | Stock Option (Right to Buy) | |
| Tango Therapeutics Inc | Adam Crystal | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 81,250 | 81,250 | - | 0 | Common Stock | |
| C4 Therapeutics Inc | Adam Crystal | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2023 | 3,750 | 21,398 | - | - | Common Stock | |
| C4 Therapeutics Inc | Adam Crystal | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2023 | 3,750 | 18,750 | - | - | Performance Restricted Stock Units | |
| C4 Therapeutics Inc | Adam Crystal | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.78 per share. | 30 Jan 2023 | 1,301 | 20,097 | - | 7.8 | 10,122 | Common Stock |
| C4 Therapeutics Inc | Adam Crystal | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.01 per share. | 26 May 2022 | 1,102 | 17,648 | - | 7.0 | 7,725 | Common Stock |
| C4 Therapeutics Inc | Adam Crystal | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 118,000 | 118,000 | - | - | Stock Option (Right to Buy) | |
| C4 Therapeutics Inc | Adam Crystal | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 26,250 | 26,250 | - | - | Performance Restricted Stock Units | |
| C4 Therapeutics Inc | Adam Crystal | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.49 per share. | 04 Jan 2022 | 15,000 | 30,000 | - | 6.5 | 97,350 | Common Stock |
| C4 Therapeutics Inc | Adam Crystal | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2022 | 15,000 | 112,292 | - | - | Stock Option (Right to Buy) | |
| C4 Therapeutics Inc | Adam Crystal | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 31.59 per share. | 04 Jan 2022 | 13,946 | 16,054 | - | 31.6 | 440,547 | Common Stock |
| C4 Therapeutics Inc | Adam Crystal | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 32.66 per share. | 04 Jan 2022 | 1,054 | 15,000 | - | 32.7 | 34,420 | Common Stock |
| C4 Therapeutics Inc | Adam Crystal | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2021 | 5,000 | 127,292 | - | - | Stock Option (Right to Buy) | |
| C4 Therapeutics Inc | Adam Crystal | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.49 per share. | 22 Dec 2021 | 5,000 | 15,000 | - | 6.5 | 32,450 | Common Stock |
| C4 Therapeutics Inc | Adam Crystal | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Oct 2021 | 10,000 | 132,292 | - | - | Stock Option (Right to Buy) | |
| C4 Therapeutics Inc | Adam Crystal | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.49 per share. | 08 Oct 2021 | 10,000 | 10,000 | - | 6.5 | 64,900 | Common Stock |
| C4 Therapeutics Inc | Adam Crystal | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.98 per share. | 01 Oct 2021 | 15,000 | 15,000 | - | 5.0 | 74,700 | Common Stock |
| C4 Therapeutics Inc | Adam Crystal | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2021 | 15,000 | 168,108 | - | - | Stock Option (Right to Buy) | |
| C4 Therapeutics Inc | Adam Crystal | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 45.32 per share. | 01 Oct 2021 | 8,176 | 5,112 | - | 45.3 | 370,563 | Common Stock |
| C4 Therapeutics Inc | Adam Crystal | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 45.99 per share. | 01 Oct 2021 | 5,112 | 0 | - | 46.0 | 235,119 | Common Stock |
| C4 Therapeutics Inc | Adam Crystal | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 44.25 per share. | 01 Oct 2021 | 1,712 | 13,288 | - | 44.3 | 75,756 | Common Stock |
| C4 Therapeutics Inc | Adam Crystal | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.98 per share. | 29 Jul 2021 | 15,000 | 15,000 | - | 5.0 | 74,700 | Common Stock |
| C4 Therapeutics Inc | Adam Crystal | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 29 Jul 2021 | 15,000 | 0 | - | 45 | 675,000 | Common Stock |
| C4 Therapeutics Inc | Adam Crystal | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jul 2021 | 15,000 | 183,108 | - | - | Stock Option (Right to Buy) | |
| C4 Therapeutics Inc | Adam Crystal | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.50 per share. | 01 Jul 2021 | 15,000 | 15,000 | - | 6.5 | 97,500 | Common Stock |
| C4 Therapeutics Inc | Adam Crystal | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2021 | 15,000 | 142,292 | - | - | Stock Option (Right to Buy) | |
| C4 Therapeutics Inc | Adam Crystal | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 37.93 per share. | 01 Jul 2021 | 13,300 | 1,700 | - | 37.9 | 504,420 | Common Stock |
| C4 Therapeutics Inc | Adam Crystal | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 38.38 per share. | 01 Jul 2021 | 1,700 | 0 | - | 38.4 | 65,246 | Common Stock |